MindMed

Mind Med

Biotechnology, 1 World Trade CTR Ste 8500, New York, 10007, United States, 51-200 Employees

mindmed.co

  • facebook
  • twitter
  • instagram
  • LinkedIn

phone no Phone Number: 16*********

Who is MINDMED

MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our ...

Read More

map
  • 1 World Trade CTR Ste 8500, New York, New York, 10007, United States Headquarters: 1 World Trade CTR Ste 8500, New York, New York, 10007, United States
  • 2019 Date Founded: 2019
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies
  • Robert Barrow CEO:   Robert Barrow

industries-icon Industry: Biotechnology

SIC SIC Code: 2833 | NAICS Code: 32 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from MINDMED

MindMed Org Chart and Mapping

Robert Barrow

Chief Executive Officer

Employees

Nicholas Hall

Scientist Pharmaceutical Development

Damon May

Digital Clinical Senior Manager

Kristopher Justo

Director of Information Technology

Alex Deschamps

Associate Manager, Clinical Research

Francois Lilienthal

Chief Commercial Officer (Cco)

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding MindMed

Answer: MindMed's headquarters are located at 1 World Trade CTR Ste 8500, New York, 10007, United States

Answer: MindMed's phone number is 16*********

Answer: MindMed's official website is https://mindmed.co

Answer: MindMed's revenue is $10 Million to $25 Million

Answer: MindMed's SIC: 2833

Answer: MindMed's NAICS: 32

Answer: MindMed has 51-200 employees

Answer: MindMed is in Biotechnology

Answer: MindMed contact info: Phone number: 16********* Website: https://mindmed.co

Answer: MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access